Title: 1α,24(S)-DIHYDROXY VITAMIN D$_2$, ITS FORMATION AND USE

Abstract

1α,24(S)-Dihydroxy vitamin D$_2$ which is useful as an active compound of pharmaceutical compositions for the treatment of disorders of calcium metabolism and for various skin disorders. The invention also includes preparation of synthetic 1α,24(S)-dihydroxy vitamin D$_2$ starting from ergosterol which is converted in six steps to 24-hydroxyergosterol. 24-Hydroxyergosterol is irradiated and thermally converted to 24-hydroxy vitamin D$_2$ which is converted in six steps to 1α,24(S)-dihydroxy vitamin D$_2$. The syntheses also produce novel intermediates.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AT  | Austria       | FR  | France       |
| AU  | Australia     | GA  | Gabon        |
| BB  | Barbados      | GB  | United Kingdom |
| BE  | Belgium       | GN  | Guinea       |
| BF  | Burkina Faso  | GR  | Greece       |
| BG  | Bulgaria      | HU  | Hungary      |
| BJ  | Benin         | IE  | Ireland      |
| BR  | Brazil        | IT  | Italy        |
| BY  | Belarus       | JP  | Japan        |
| CA  | Canada        | KP  | Democratic People's Republic of Korea |
| CF  | Central African Republic |
| CG  | Congo         | KR  | Republic of Korea |
| CH  | Switzerland   | KZ  | Kazakhstan   |
| CI  | Côte d'Ivoire | LI  | Liechtenstein |
| CM  | Cameroon      | LK  | Sri Lanka    |
| CN  | China         | LU  | Luxembourg   |
| CS  | Czechoslovakia | LV  | Latvia       |
| CZ  | Czech Republic | MC | Monaco      |
| DE  | Germany       | MG  | Madagascar  |
| DK  | Denmark       | ML  | Mali         |
| ES  | Spain         | MN  | Mongolia     |
| FI  | Finland       | MR  | Mauritania   |
| MW  | Malawi        | NE  | Niger        |
| NL  | Netherlands   | NO  | Norway       |
| NZ  | New Zealand   | PL  | Poland       |
| PT  | Portugal      | RU  | Russian Federation |
| RO  | Romania       | SD  | Sudan        |
| SE  | Sweden        | SI  | Slovenia     |
| SK  | Slovak Republic |
| SN  | Senegal       | TD  | Chad         |
| TG  | Togo          | UA  | Ukraine      |
| US  | United States of America |
| UZ  | Uzbekistan    | VN  | Viet Nam     |
This application is a continuation-in-part of U.S. application Serial No. 07/637,867, filed January 8, 1991, and International Application No. PCT/US92/00313, filed January 7, 1992, and which designated the U.S.

TECHNICAL FIELD

This invention relates to biologically active vitamin D$_3$ compounds. More specifically, this invention relates to the hormonally active, natural metabolite 1α,24(S)-dihydroxy vitamin D$_3$ and to methods of preparing this metabolite and the nonbiological epimer 1α,24(R)-dihydroxy vitamin D$_3$. This invention also relates to a pharmaceutical composition which includes a pharmaceutically effective amount of 1α,24(S)-dihydroxy vitamin D$_3$, and to a method of controlling abnormal calcium metabolism by administering a pharmaceutically effective amount of the compound.

BACKGROUND OF THE INVENTION

Vitamin D and its active metabolites are known to be important in regulating calcium metabolism in animals and humans. The naturally occurring form of vitamin D in animals and humans is vitamin D$_3$. It has been shown that in animals, including humans, vitamin D$_3$ is activated by being hydroxylated in the C$_{25}$ position in the liver, followed by 1α-hydroxylation in the kidney to
produce the hormone 1α,25-dihydroxy vitamin D₃ ["1α,25-(OH)₂D₃"]). See, U.S. Patent No. 3,880,894. The major physiological pathway for catabolism of the vitamin D₃ metabolites, 25-hydroxy vitamin D₃ and 1α,25-(OH)₂D₃, is initiated by C₂₅-oxidation.


Vitamin D₂ is the major, naturally occurring form of vitamin D found in plants. Vitamin D₂ differs structurally from vitamin D₃ in that vitamin D₂ has a methyl group at C₂₅ and has a double bond between C₂₂ and C₂₃.

Shortly after their discovery, it seemed apparent that vitamin D₂ and vitamin D₃ had similar, if not equivalent, biological activity. It has also been commonly believed that the metabolism (i.e., the activation and catabolism) of vitamin D₂ was the same as for vitamin D₃. See, Harrison's Principles of Internal Medicine: Part Seven, "Disorders of Bone and Mineral Metabolism: Chap. 35," in E. Braunwald, K.J. Isselbacher, R.G. Petersdorf, J.D. Wilson, J.B. Martin and H.S. Fauci (eds.), Calcium, Phosphorus and Bone Metabolism: Calcium Regulating Hormones, McGraw-Hill, New York, pp. 1860-1865. In this regard, the active form of vitamin D₂ is believed to be 1α,25-dihydroxy vitamin D₂ ["1α,25-(OH)₂D₂"]. Further, 24-hydroxy derivatives of 25-hydroxy vitamin D₂ and 1α,25-(OH)₂D₂, that is, 24,25-dihydroxy vitamin D₂ and 1α,24,25-trihydroxy vitamin D₂, are known, suggesting that catabolism of vitamin D₂, like vitamin D₃, proceeds through the same C₂₅ oxidation step. Jones, G., Rosenthal, D., Segev, D., Mazur, Y., Frolov, F., Halfon, Y., Robinavich, D. and Shakked, Z., Biochemistry, 18:1094-1101 (1979).

It has recently been found, however, that an active analogue of vitamin D₂, 1α-hydroxy vitamin D₂
"1α-(OH)D₂" has pharmacological properties distinctly different than those exhibited by its vitamin D₃ counterpart, 1α-hydroxy vitamin D₃. U.S. Patent 5,104,864 discloses that 1α-(OH)D₂ will reverse the loss of bone mass in human osteoporotic patients when administered at dosages of 2.0 µg/day or higher. Because of toxicity, dosage levels of 2.0 µg/day or greater are not safely obtained with 1α-(OH)D₃.

Such distinct pharmacological properties may be explained fully, or in part, by the present inventors' discovery that pharmacological dosages of 1α-(OH)D₂ administered to humans are metabolized in part to biologically active 1α,24(S)-dihydroxy vitamin D₃ ("1α,24(S)-(OH)₂D₂"). As explained in more detail below, the hydroxylation at the carbon-24 position of the 1-hydroxylated vitamin D₃ molecule, represents an activation pathway peculiar to the vitamin D₃ molecule.

While 1α,24(S)-dihydroxy vitamin D₃ and 1α,24(R)-dihydroxy vitamin D₃ ("1α,24(R/S)-(OH)₂D₃") have been chemically synthesized (U.S. Patent No. 4,022,891) it has not been demonstrated that either is a natural compound found in biological systems. Furthermore, the present inventors have discovered that 1α,24(S)-(OH)₂D₂ has distinctly different biological activity from that exhibited by 1α,24(R/S)-(OH)₂D₃. For example, Ishizuka et al. have found that 1α,24(R)-(OH)₂D₃ binds the 1,25-(OH)₂D₃ receptor site more tightly than does 1,25-(OH)₂D₃ itself. Ishizuka, S., Bannai, K., Naruchi, T. and Hashimoto, Y., Steroids, 37:1,33-42 (1981); Ishizuka, S., Bannai, K., Naruchi, T. and Hashimoto, Y., Steroids, 39:1,53-62 (1982). Using a similar assay, the present inventors have discovered that the 1α,24(S)-(OH)₂D₂ is two-fold less competitive in binding the 1,25-(OH)₂D₃ receptor site than is 1,25-(OH)₂D₃. The present inventors have also found that 1α,24(S)-(OH)₂D₂ shows a relatively poor binding affinity
for the vitamin D serum binding protein which is evidence of a rather short half life indicative of low toxicity.

The present inventors have demonstrated the presence of circulating $1\alpha,24(S)-(OH)_2D_2$ in humans administered $1\alpha-(OH)D_2$. This indicates that in animals and man, vitamin D$_3$ is naturally metabolized to both $1\alpha,25-(OH)_2D_2$ and $1\alpha,24(S)-(OH)_2D_2$. The relative ratios of the two vitamin D$_2$ hormones appear to vary according to the precursor and the amount of precursor presented to the C$_{25}$ pathway. Thus it appears that as dosages of $1\alpha-(OH)D_2$ are increased, the ratio of $1\alpha,24(S)-(OH)_2D_2$ to $1\alpha,25-(OH)_2D_2$ increases.

These results which are presented in more detail below, indicate that $1\alpha,24(S)-(OH)_2D_2$ has the desirable characteristic of high biological activity with low toxicity. The fact that $1\alpha,24(S)-(OH)_2D_2$ is a significant metabolite when pharmacological levels of $1\alpha-(OH)D_2$ are administered indicates that $1\alpha,24(S)-(OH)_2D_2$ may be mediating the desirable pharmacological effects of $1\alpha-(OH)D_2$ and is a useful therapeutic drug for treating various types of disorders involving calcium metabolism.

**SUMMARY OF THE INVENTION**

The invention provides synthetic $1\alpha,24(S)-(OH)_2D_2$ which is a biologically produced active form of vitamin D$_2$. The biological form may also be referred to as $1\alpha,24(S)$-dihydroxy ergocalciferol and is represented by the structure given hereinafter. The biological form of the compound has potent biological activity and rapid systemic clearance, indicating low toxicity.

The invention also encompasses a novel method of producing $1\alpha,24(S)$-dihydroxy vitamin D$_2$ which entails using ergosterol as a starting material, forming 24-hydroxy vitamin D$_2$ and then, 1\alpha-hydroxylating the 24-hydroxy compounds and separating the $1\alpha,24(S)$-dihydroxy vitamin D$_2$ epimer from the
1α,24(R)-dihydroxy vitamin D₃ epimer. In the course of this synthesis, novel intermediates are also produced.

The compound of the invention is useful in the treatment of various diseases characterized by vitamin D deficiency and various bone depleitive disorders, in particular, treatment without the concomitant incidence of hypercalcemia or hypercalciuria. The compound of the invention is advantageously used as an active ingredient of pharmaceutical compositions for vitamin D deficiency diseases, for reversing or preventing the loss of bone mass or bone mineral content in persons predisposed to developing such loss, and for stabilizing bone density in persons suffering from renal osteodystrophy.

The compound of the invention is also useful as a topical agent for treatment of certain skin disorders. The compound of the invention is advantageously used as an active ingredient for topical compositions which may also include other agents capable of ameliorating skin disorders.

Other advantages and a better appreciation of the specific adaptations, compositional variations, and physical and chemical attributes of the present invention will be gained upon an examination of the following detailed description of the invention, taken in conjunction with the accompanying drawings.

**BRIEF DESCRIPTION OF THE DRAWINGS**

The present invention will hereinafter be described in conjunction with the appended drawings, wherein like designations refer to like elements throughout and in which:

- Figure 1 illustrates preparative steps for the synthesis of 24-hydroxy vitamin D₃;
- Figure 2 illustrates preparative steps for the synthesis of 1α,24(S)-dihydroxy vitamin D₃ starting with 24-hydroxy vitamin D₃;
- Figure 3 is a reverse phase high pressure liquid chromatography profile of biological 1α,24-dihydroxy
vitamin D₂ and the R and S epimers of synthetic 1α,24-dihydroxy vitamin D₂; and

Figure 4 is a graph illustrating the relative binding affinities of 1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂.

**DETAILED DESCRIPTION**

The present invention provides synthetic 1α,24(S)-dihydroxy vitamin D₂ [1α,24(S)-(OH)₂-D₂].

As used herein, the terms "biological activity", "biologically active", "bioactive", or "biopotent" are meant to refer to biochemical properties of compounds such as affecting metabolism, e.g., affecting serum calcium concentration, or binding to an appropriate receptor protein, e.g., binding to vitamin D receptor protein. The term "substantially pure" in reference to compounds or substances means a purity of at least 90%.

In one of its aspects, the invention encompasses the biologically active compound of the formula (I):

![Chemical Structure](image)

i.e., 1α,24(S)-dihydroxy vitamin D₂.

In another aspect, the invention involves the preparation of 1α,24(S)-dihydroxy vitamin D₂. Synthesis of 1α,24(S)-dihydroxy vitamin D₂ is accomplished according to the schema presented in Figures 1 and 2. Hereinafter when reference is made to a 24-hydroxy compound, unless specified, it will be presumed that the compound is an epimeric mixture of the R and S forms. As seen in Figure 1, the synthesis uses ergosterol as
the starting material. Ergosterol is converted to 24-hydroxyergosterol (5,7,22 ergostatriene-3β,24-diol (7)) by a five-step process. The 24-hydroxy ergosterol is then irradiated and thermally converted by methods well known in the art to yield 24-hydroxy vitamin D₂. As seen in Figure 2, 24-hydroxy vitamin D₂ is then hydroxylated in a five-step process to yield 1α,24-dihydroxy vitamin D₂, using a procedure similar to that described by Paaren, et al., *J. Org. Chem.*, vol. 45, p. 3253 (1980), from which the epimers are separated.

Specifically, ergosterol is acetylated to form the 3β-acetate (2). An adduct (3) is then formed with the B-ring of the ergosterol structure by reaction of the 3β-acetate with a triazoline dione. The adduct (3) is then ozonated to truncate the side chain to form a C-21 aldehyde (4). The side chain is reestablished by reaction of the resulting aldehyde with the appropriate keto-compound to yield the 24-enone (5). The enone is then converted to the 24-methyl, 3β,24-dihydroxy adduct (6). This adduct is then reacted with a lithium aluminum hydride to deprotect the adduct and yield 24-hydroxy ergosterol (7). The 24-hydroxy ergosterol is then irradiated and thermally treated to form 24-hydroxy vitamin D₂. The 24-hydroxy vitamin D₂ is then tosylated to yield 3β-tosylate of the 24-hydroxy vitamin D₂. The tosylate is displaced by solvolyis to yield the 6-methoxy-24-hydroxy-3,5-cyclo vitamin D₂. The cyclovitamin D₂ is subjected to allylic oxidation to form the 1α, 24-dihydroxy cyclovitamin derivative. The 1α,24-dihydroxy cyclovitamin derivative is sequentially solvolyzed and subjected to a Diels-Alder type reaction which removes the 6-methoxy group and separates the 1α,24-dihydroxy vitamin D₂ (5,6 cis) from the 5,6 trans

1α,24-dihydroxy vitamin D₂.

The 1α,24-(OH)₂D₂ is subjected to reverse phase high pressure liquid chromatography to separate the two
epimers and recover the epimeric form of the invention, 1\alpha,24(S)-(OH)_{2}D_{2}.

The compound of the invention is applicable to various clinical and veterinary fields, and is particularly useful for the treatment of abnormal metabolism of calcium and phosphorus. Specifically, 1\alpha,24(S)-dihydroxy vitamin D_{2} is intended to be used, for example, to stimulate osteoblastic activity, as measured by serum levels of osteocalcin. Osteocalcin is one of the major proteins in the bone matrix. The 1\alpha,24(S)-dihydroxy vitamin D_{2} binds to the vitamin D serum binding protein more weakly than does 1,25-(OH)_{2}D_{3}, indicative of rapid clearance and low toxicity, which enhances its pharmaceutical properties.

In a further aspect, the invention entails a method of controlling calcium metabolism, such as for treating abnormal calcium metabolism caused, e.g., by liver failure, renal failure, gastrointestinal failure, etc. The 1\alpha,24(S)-dihydroxy vitamin D_{2} can be used to treat prophylactically or therapeutically vitamin D deficiency diseases and related diseases, for example, renal osteodystrophy, steatorrhea, anticonvulsant osteomalacia, hypophosphatemic vitamin D-resistant rickets, osteoporosis, including postmenopausal osteoporosis, senile osteoporosis, steroid-induced osteoporosis, and other disease states characteristic of loss of bone mass, pseudodeficiency (vitamin D-dependent) rickets, nutritional and malabsorptive rickets, osteomalacia and osteopenias secondary to hypoparathyroidism, post-surgical hypoparathyroidism, idiopathic hypothyroidism, pseudoparathyroidism, and alcoholism.

1\alpha,24(S)-Dihydroxy vitamin D_{2} is also of value for the treatment of hyperproliferative skin disorders such as psoriasis, eczema, lack of adequate skin firmness, dermal hydration, and sebum secretion, and is valuable for the treatment of breast and colon cancer.
1α,24(S)-Dihydroxy vitamin D₂ is useful as an active compound in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogs of active forms of vitamin D₃, when applied, for example, to diseases induced by abnormal metabolism of calcium. These pharmaceutical compositions constitute another aspect of the invention.

The pharmacologically active compound of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. For example, the 1α,24(S)-dihydroxy vitamin D₂ can be employed in admixtures with conventional excipients, e.g., pharmaceutically acceptable carrier substances suitable for enteral (e.g., oral), parenteral, or topical application which do not deleteriously react with the active compound.

Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., almond oil, corn oil, cottonseed oil, peanut oil, olive oil, coconut oil), mineral oil, fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates (e.g., lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.

The pharmaceutical preparations can be sterilized and, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active compounds, for example, vitamin D₃ and its 1α-hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens, calcitonin, biphosphonates, calcium supplements, cobalamin, pertussis toxin and boron.
-10-

For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solution, as well as suspensions, emulsions, or implants, including suppositories. Parenteral administration suitably includes subcutaneous, intramuscular, or intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption. Ampoules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. A syrup, elixir, or the like can be used if a sweetened vehicle is desired.

For topical application, suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water, for example, mineral oil, almond oil, self-emulsifying beeswax, vegetable oil, white soft paraffin, and propylene glycol. Suitable formulations include, but are not limited to, creams, ointments, lotions, solutions, suspensions, emulsions, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g., preservatives, stabilizers, demulsifiers, wetting agents, etc. A cream preparation in accordance with the present invention suitably includes, for example, mixture of water, almond oil, mineral oil and self-emulsifying beeswax; an ointment preparation suitably includes, for example, almond oil and white soft paraffin; and a lotion preparation suitably includes, for example, dry propylene glycol.

Topical preparations of the compound in accordance with the present invention useful for the treatment of skin disorders may also include epithelialization-inducing agents such as retinoids (e.g., vitamin A), chromanols such as vitamin E, β-agonists such as isoproterenol or cyclic adenosine monophosphate (cAMP), anti-inflammatory agents such as corticosteroids (e.g.,
hydrocortisone or its acetate, or dexamethasone) and
keratoplastic agents such as coal tar or anthralin.
Effective amounts of such agents are, for example,
vitamin A about 0.003 to about 0.3% by weight of the
composition; vitamin E about 0.1 to about 10%;
isoproterenol about 0.1 to about 2%; cAMP about 0.1 to
about 1%; hydrocortisone about 0.25 to about 5%; coal
tar about 0.1 to about 20%; and anthralin about 0.05 to
about 2%.

For rectal administration, the compound is formed
into a pharmaceutical composition containing a
suppository base such as cacao oil or other
triglycerides. To prolong storage life, the composition
advantageously includes an antioxidant such as ascorbic
acid, butylated hydroxyanisole or hydroquinone.

For treatment of calcium metabolic disorders, oral
administration of the pharmaceutical compositions of the
present invention is preferred. Generally, the compound
of this invention is dispensed by unit dosage form
comprising about 0.5 µg to about 25 µg in a
pharmacologically acceptable carrier per unit dosage.
The dosage of the compound according to this invention
generally is about 0.01 to about 1.0 µg/kg/day,
preferably about 0.04 to about 0.3 µg/kg/day.

For topical treatment of skin disorders, the dosage
of the compound of the present invention in a topical
composition generally is about 0.01 µg to about 50 µg
per gram of composition.

For treatment of cancers, the dosage of
1α,24(S)-(OH)₂D₃ in a locally applied composition
generally is about 0.01 µg to 100 µg per gram
composition.

It will be appreciated that the actual preferred
amounts of active compound in a specific case will vary
according to the efficacy of the specific compound
employed, the particular compositions formulated, the
mode of application, and the particular site and
organism being treated. For example, the specific dose
for a particular patient depends on the age, body weight, general state of health and sex, on the diet, on the timing and mode of administration, on the rate of excretion, and on medications used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.

In a still further aspect, the compound of the present invention can also be advantageously used in veterinary compositions, for example, feed compositions for domestic animals to treat or prevent hypocalcemia. Generally, the compound of the present invention is dispensed in animal feed such that normal consumption of such feed provides the animal about 0.01 to about 1.0 µg/kg/day.

The following examples are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples proton nuclear magnetic resonance (¹H NMR) spectra were recorded with a Bruker AM--400(400 MHz) with aspect 3000 Computer in CDCl₃ solutions with CHCl₃ as an internal standard. Chemical shifts are reported in ppm. Ultraviolet spectra were recorded with a Hitachi U-2000 Spectrophotometer and are reported for ethanol solutions.

Example 1: Generation, purification and identification of 1α,24(?)-(OH)₂D₂ in human liver cells incubated with 1α-(OH)D₂

Substantially pure 1α-(OH)D₂ was obtained from Bone Care International, Inc. of Madison, Wisconsin. The 1α-(OH)D₂ was cultured for 48 hours with cells derived from a human hepatoma, Hep 3B, in medium devoid of fetal calf serum using known methods in the art.
Lipid extracts of the combined medium and cells were generated by known methods in the art and were subjected to high pressure liquid chromatography (HPLC) on Zorbax-SIL developed with hexane/isopropanol/methanol (91:7:2). The putative 1α,24(?)-(OH)2D2 metabolite eluted between the parent 1α-(OH)D2 and standard 1α,25-(OH)2D2 (also obtained from Bone Care International, Inc. of Madison, Wisconsin). (As used herein, the term "1α,24(?)-(OH)2D2" is meant to indicate that the epimeric form has not been identified.) The 1α,24(?)-(OH)2D2 was further purified by this HPLC system before the metabolite's identification was undertaken using mass spectrometry analysis.

The purified metabolite was more polar than the starting material, 1α-(OH)D2 and thus was tentatively concluded to be a dihydroxy vitamin D2 metabolite. This metabolite also possessed the vitamin D chromophore, indicating retention of the cis-triene system of vitamin D. Since the metabolite was derived from 1α-(OH)D2, its structure was thus 1α,X-(OH)2D2 where "X" indicates the position of the second hydroxyl group.

The trimethylsilyl-derivative of the 1α,X-(OH)2D2 was prepared according to known methods in the art and mass spectrometry was performed on the TMS-derivative and the native compound. The TMS-derivative was analyzed by GC-MS, and the identification was mainly derived from interpretation of the fragmentation pattern of the pyro-metabolite. The molecular ion possessed a m/z of 644 indicating a dihydroxy vitamin D2 with addition of three TMS groups accounting for 216 units of additional mass. Since 1α-(OH)D2 has 3β- and 1α- groups and the putative metabolite had one additional hydroxyl, all three hydroxyls were thus derivatized. Distinctive fragments were found at m/z 601, 511, 421, 331 representing loss of a 43 mass unit of fragment alone or in addition to one, two or three TMS groups of 90 units each. This pattern was most likely explained by cleavage of the C-24 to C-25 bond loss of C3H7 accounting...
for 43 mass units. This represents loss of the C_{26}-C_{25}-C_{27} fragment. Furthermore, the mass spectrum lacked the m/z 131 fragment characteristic of all 25-hydroxylated vitamin D compounds.

The mass spectrum showed the m/z 513 fragment indicating loss of 131 mass units due to A-ring cleavage with loss of C_{2}-C_{3}-C_{4} also characteristic of vitamin D compounds. The mass spectrum also contained m/z 143 which was probably derived from C-24 to C-23 cleavage and a loss of a methyl group. The unusual loss of 43 units indicating C_{24}-C_{25} fragility coupled with the loss of a fragment due to C_{25}-C_{24} cleavage indicated that the extra hydroxyl in 1α, X-(OH)_{2}D_{2} was at carbon-24. Thus, the structure was identified as 1α,24(?)-(OH)_{2}D_{2}.

The native metabolite was analyzed by direct probe mass spectrometry. This analysis was consistent with a hydroxyl in the 24 position, and was also consistent with the GC-MS analysis of the TMS-derivative described above. The native metabolite showed the expected molecular ion at m/z 428 and a distinctive fragment at m/z 367, indicating the loss of one water and the C_{25}-C_{26}-C_{27} fragment of 43 mass units.

Example 2: Synthesis of 1α,24(S)-dihydroxy vitamin D_{2} (22E)-5,7,22-ergostatriene-3β-yl acetate (2)

To a solution of 50 gm (0.13 mol) of ergosterol (1) in 300 ml of anhydrous pyridine was added 33.3 ml (0.35 mol) of acetic anhydride. The mixture was stirred at room temperature overnight and then 600 ml of water was added. The precipitate was filtered and washed three times with 200 ml portions of acetonitrile and then air dried to yield 42.0 g (74%) of (2).

22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1.2-diyld)23,24-dinor-6-cholene-3β-yl acetate (4)

To a solution of 33.0 g (0.075 mol) of ergosterol acetate (2) in 1000 ml of chloroform was added 13.2 g
(0.075 mol) of 4-phenyl-1,2,4-triazoline-3,5-dione. The solution of the thus formed (3) was stirred at room temperature for 30 min. and then 5 ml of pyridine was added. The solution was cooled to -78°C and treated at -78°C with an ozone-oxygen mixture for 2 hours and then thoroughly purged with nitrogen. Then 50 ml of dimethylsulfoxide was added and the mixture was washed with 300 ml of water, then twice with 200 ml of 2N HCl and finally 300 ml of water. The organic layer was separated, dried over anhydrous MgSO₄ and concentrated to dryness in vacuo. The residue was purified on a silica gel column using 30% ethyl acetate in hexane to yield 16.0 g (39%) of the title compound as a foamy solid.

$^1$H NMR: (400 MHz; CDCl₃); δ ppm 0.85 (3H, t, 18-CH₃), 1.10 (3H, s, 19-CH₃), 1.15 (3H, d, 21-CH₃), 1.99 (3H, s, 3β-CH₃), 5.45 (1H, t, 3α-H), 6.26 (1H, d, 7-H), 6.40 (1H, d, 6-H), 7.42 (5H, m, Ph), 9.58 (1H, d, HCO).

(22E)5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)cholesta-6,22-diene-24-one-3β-yl acetate (5)

Butyllithium (1.6M solution in hexane 8.94 ml, 0.014 mol) was added to a stirred, cooled (0°C) solution of diisopropylamline (1.45 g, 0.014 mol) in dry tetrahydrofuran (20 ml) under nitrogen.

3-Methylbutan-2-one (1.23 g, 0.014 mol) in dry tetrahydrofuran (6 ml) was added dropwise at 0°C over 15 min. The solution was stirred at 0°C for 1 hr. more, then cooled to -70°C and a solution of the aldehyde (4) (6.0 g, 0.011 mol) in dry tetrahydrofuran (60 ml) was added. The temperature was raised to -20°C and kept at this temperature for 3 hrs. Then glacial acetic acid (20 ml) was added at -20°C and the solution was brought to room temperature. Ether (800 ml) and water (400 ml) were added and the organic layer was separated and washed with 10% hydrochloric acid (2 x 300 ml), saturated sodium bicarbonate solution (2 x 300 ml), and water (2 x 300 ml). Concentration gave the crude product (7.5 g) which was dissolved in tetrahydrofuran
(100 ml) containing 1.5 N-hydrochloric acid (12 ml). After refluxing for 1.5 hrs., the mixture was diluted with ether (600 ml), washed with a 5% sodium carbonate solution (2 x 200 ml) and water (2 x 200 ml), and dried (anhydrous MgSO₄). Concentration under reduced pressure gave the crude product (7.0 g). Chromatography over silica gel (50% ethyl acetate in hexane) gave the enone (5) 4.0 g (59%).

¹H NMR: (400 MHz): δ ppm 0.83 (3H, s, 18-CH₃), 0.99 (3H, s, 19-CH₃), 1.09 (6H, dd, 26 and 27-CH₂), 1.12 (3H, d, 21-CH₃), 2.0 (3H, s, 3β-CH₃CO), 2.84 (1H, m, 25-H), 5.45 (1H, m, 3a-H), 6.06 (1H, d, 23-H), 6.24 (1H, d, 7-H), 6.39 (1H, d, 6-H), 6.71 (1H, dd, 22-H), 7.42 (5H, m, Ph).

(22E)-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyI)-6,22-ergostadiene-3β,24-diol (6)

The enone (5) (3.5 g, 5.7 mmol) in dry ether (100 ml) was cooled to 0°C and methylmagnesium bromide (3.0 M solution in ether 6.8 ml, 0.02 mol) was added dropwise. After 1 hr. at 0°C, saturated ammonium chloride (100 ml) was added. The organic layer was separated. The aqueous layer was extracted with ether (2x200 ml). The combined ether phases were dried over anhydrous MgSO₄ and concentrated to dryness in vacuo to yield the crude product 3.0 g (90%) of (6).

(22E)-5,7,22-ergostatriene-3β,24-diol (7)

To a solution of 3.0 g (5.1 mmol) of (6) in dry tetrahydrofuran (250 ml) was added 3.6 g (0.09 mol) of lithium aluminum hydride. The mixture was heated under reflux for 3 hrs., cooled with ice water bath and reaction mixture decomposed by the cautious dropwise addition of ice water (5 ml). The mixture was filtered and the filtrate was concentrated in vacuo to remove most of the tetrahydrofuran. The residue was dissolved in 200 ml of ethyl acetate and washed twice with
-17-

saturated NaCl solution (2x200 ml), dried over anhydrous MgSO₄ and concentrated in vacuo. The residue was purified on a silica gel column using 30% ethyl acetate in hexane to yield 1.5 g (71%) of (Z).

1H NMR: (400 MHz, CDCl₃): δppm 0.64 (3H, s, 18-H), 0.88 (6H, dd, 26 and 27-CH₃), 0.93 (3H, s, 19-CH₃), 1.06 (3H, d, 21-CH₃), 1.19 (3H, s, 28-CH₃), 3.55 (1H, m, 3α-H), 5.36 (1H, d, 7-H), 5.42 (2H, m, 22 and 23-H), 5.52 (1H, d, 6-H). UV (ethanol) λ_max: 282 nm.

24-hydroxyvitamin D₃ (8)

One gram (2.4 mmol) of (Z) was dissolved in 250 ml of ether and benzene (4:1) and irradiated with stirring under nitrogen in a water-cooled quartz immersion well using a Hanovia medium-pressure UV lamp for 2 hrs. The solution was concentrated in vacuo, redissolved in 100 ml of ethanol and heated under reflux overnight. The solution was concentrated to dryness in vacuo and the residue was purified on a silica gel column using 30% ethyl acetate in hexane to yield 0.55 g (55%) of (8).

1H NMR: (400 MHz, CDCl₃): δppm 0.57 (3H, s, 18-CH₃), 0.92 (6H, dd, 26 and 27-CH₃), 1.06 (3H, d, 21-CH₃), 1.20 (3H, s, 28-CH₃), 3.93 (1H, m, 3-H), 4.79 (1H, m (sharp), 19-H), 5.01 (1H, m, (sharp), 19-H), 5.43 (2H, m, 22 and 23-H), 6.02 (1H, d, 7-H), 6.22 (1H, d, 6-H). UV (ethanol) λ_max: 265 nm.

24-hydroxyvitamin D₃ tosylate (9)

To a solution of 0.55 g (1.3 mmol) of (8) dissolved in 5 ml of anhydrous pyridine was added 0.6 g (3.2 mmol) of tosyl chloride. The mixture was stirred under nitrogen at 5°C for 20 hrs. The reaction mixture was poured into 100 ml of cold saturated NaHCO₃ solution and extracted with ether (3 x 100 ml). The combined organic extracts were washed with 5% HCl solution (2 x 200 ml) saturated sodium bicarbonate solution (2 x 200 ml) and
saturated NaCl solution (2 x 200 ml), dried over anhydrous MgSO₄ and concentrated in vacuo to yield 0.62 g (84%) of (9).

^1^H NMR: (400 MHz, CDCl₃): δ ppm 0.57 (3H, s, 18-CH₃), 0.92 (6H, dd, 26 and 27-CH₃), 1.08 (3H, d, 21-CH₃), 1.24 (3H, s, 28-CH₃), 2.43 (3H, s, CH₃ (tosylate), 4.69 (1H, m, 3-H), 4.77 (1H, m, (sharp), 19-H), 5.0 (1H, m, (sharp), 19-H), 5.42 (2H, m, 22 and 23-H), 6.03 (1-H, d, 7-H), 6.25 (1-H, d, 6-H) 7.31 and 7.83 (4H, d, aromatic).

24-hydroxy-3,5-cyclovitamin D₂ (10)

To a solution of 0.6 g (1.06 mmol) of (9) dissolved in 50 ml of anhydrous methanol was added sodium bicarbonate 4.0 (0.047 mol). The mixture was heated at reflux for 6 hrs. The reaction mixture was concentrated in vacuo. Water (100 ml) was added followed by extraction with ether (2 x 200 ml). The combined ether extracts were dried over anhydrous MgSO₄ and concentrated to dryness in vacuo to yield 450 mg (100%) of (10) as an oil.

1α,24-dihydroxy-3,5-cyclovitamin D₂ (11)

tert-Butyl hydroperoxide (870 μl (2.61 mmol); 3M in toluene) was added to a suspension of 73 mg (0.66 mmol) of selenium dioxide in 50 ml of anhydrous dichloromethane under nitrogen. The mixture was stirred at room temperature under nitrogen for 3 hrs. Then 0.1 ml of anhydrous pyridine was added followed by a solution of 450 mg (1.06 mmol) of (10) dissolved in 15 ml of anhydrous dichloromethane. The mixture was stirred under nitrogen at room temperature for 10 min. then 25 ml of 10% NaOH solution was added and the mixture was extracted with ether (3 x 100 ml). The combined ether extracts were washed with 10% NaOH solution (2 x 100 ml), water (2 x 100 ml), saturated sodium chloride solution (2 x 100 ml), dried over
anhydrous MgSO₄ and concentrated to dryness in vacuo. The residue was purified on a silica gel column using a mixture of 30% ethyl acetate in hexane to yield 110 mg (24%) of (11).

1H NMR: (400 MHz, CDCl₃): δ ppm, 0.55 (3H, s, 18CH₃), 0.90 (6H, dd, 26 and 27-CH₃), 1.03 (3H, d, 21-CH₃), 1.19 (3H, s, 28-CH₃), 3.25 (3H, s, -OCH₃), 4.19 (1H, d, 6-H), 4.19 (1H, m, 1-H), 4.92 (2H, d, 7-H), 5.15 (1H, m, (sharp), 19-H), 5.2 (1H, m, (sharp), 19-H), 5.42 (2H, m, 22 and 23-H).

5,6-cis and 5,6-trans-1α,24-dihydroxy vitamin D₃ (12, 13)

1α,24-dihydroxy-3,5-cyclovitamin D₃ (11) 110 mg (0.25 mmol) was dissolved in 2.0 ml of dimethylosulfoxide and 1.5 ml of acetic acid and heated at 50°C under nitrogen for 1 hr. The solution was poured over ice and 50 ml of saturated NaHCO₃ solution. The mixture was extracted with ether (3 x 100 ml). The combined ether extracts were washed with saturated NaHCO₃ solution (3 x 100 ml), water (2 x 100 ml), saturated NaCl solution (2 x 200 ml), dried over anhydrous MgSO₄ and concentrated in vacuo to yield the crude product 100 mg (93%) of (12) and (13).

5,6-cis-1α,24-dihydroxy vitamin D₃ (12)

To a solution of (12) and (13) in 5 ml of ethyl acetate was added 20 mg (0.2 mmol) of maleic anhydride and the mixture was stirred at 35°C for 24 hrs. under nitrogen. The solution was concentrated to dryness in vacuo. The residue was purified on a silica gel column using 50% ethyl acetate in hexane to yield 20 mg (22%) of (12).

1H NMR: (400 MHz, CDCl₃): δ ppm 0.57 (3H, s, 18-CH₃), 0.89 (6H, dd, 26 and 27-CH₃), 1.04 (3H, d, 21-CH₃), 1.21 (3H, s, 28-CH₃), 4.23 (1H, m, 3-H), 4.40 (1H, m, 1-H), 5.0 (1H, m, (sharp), 19-H), 5.33 (1H, m,
(sharp), 19-H), 5.44 (2H, m, 22 and 23-H), 6.01 (1H, d, 7-H), 6.37 (1H, d, 6-H). UV (ethanol) $\lambda_{max}$: 265 nm.

**1α,24(S)-dihydroxy vitamin D$_2$ (14)**

The 24 epimers of 1α,24-(OH)$_2$D$_2$ were separated by high pressure liquid chromatography, performed on a Waters instrument using a reverse-phase Supelco C-8 prep. column (25 cm x 21.2 mm; particle size 12 μm) with the solvent system, acetonitrile:water, 60:40, 10 mL/min. The epimers were given the designations epimer 1 and epimer 2. Under these conditions the retention time of epimer 1 was 63 min., and the retention time of epimer 2 was 71 min. Using x-ray crystallography, it was determined that the stereochemistry of epimer 2 was 1α,24(R)-(OH)$_2$D$_2$. The stereochemistry of epimer 1 was therefore known to be 1α,24(S)-(OH)$_2$D$_2$.

**Example 3:** Identification of the stereochemistry and the biologically derived 1α,24(?)-(OH)$_2$D$_2$ metabolite by comparison to the chemically synthesized epimers, 1α,24(S)-(OH)$_2$D$_2$ and 1α,24(R)-(OH)$_2$D$_2$.

The stereochemistry of the biologically generated metabolite obtained as described in example 1, above, was compared by high pressure liquid chromatography and gas chromatography to the chemically synthesized epimers obtained as described in example 2, above. Based on these comparisons, it was determined that the biologically produced metabolite has the structure, 1α,24(S)-(OH)$_2$D$_2$. Figure 3 shows a profile of the high pressure liquid chromatography experiment making this comparison. In Figure 3, epimer 1 is the chemically synthesized 1α,24(S)-(OH)$_2$D$_2$.

(a) High pressure liquid chromatographic comparisons utilized two different columns and solvent systems. On the reverse-phase column Zorbax-ODS (DuPont Instruments; 3 μ; 6.2 mm x 8 cm) utilizing the solvent system, acetonitrile:water, 60:40, 1 ml/min., the
biological metabolite emerged at 14.3 min. and
1α,24(S)-(OH)₂D₂ ran at 14.2 min.; however,
1α,24(R)-(OH)₂D₂ ran at 15.7 min.

On the straight-phase column Zorbax-SIL (Dupont
Instruments; 3 μ; 6.2 mm x 8 cm) utilizing the solvent
system, hexane:isopropanol:methanol, 94:5:1, 1 ml/min.,
the biological metabolite emerged at 22.4 min. and
1α,24(S)-(OH)₂D₂ ran at 22.4 min.; however,
1α,24(R)-(OH)₂D₂ ran at 22.8.

(b) With gas chromatography, 1α,24(S)-(OH)₂D₂
co-migrated with the biologically generated compound
whereas the retention time of 1α,24(R)-(OH)₂D₂ was quite
different (Table 1).

Table 1: Gas Chromatography Retention Times of
Pyro-Derivatives Relative to
Pyro-1α,25-(OH)₂D₃.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Relative Retention Time*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1α,24(S)-(OH)₂D₂</td>
<td>1.0165</td>
</tr>
<tr>
<td>1α,24(R)-(OH)₂D₂</td>
<td>1.0098</td>
</tr>
<tr>
<td>Biological Metabolite</td>
<td>1.0163</td>
</tr>
</tbody>
</table>

*Retention time is expressed relative to an
internal standard 1α,25-(OH)₂D₃ where the
pyro-derivatives are compared.

Example 4: Comparison of the biological activity of
1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂.

The biological activity in vitro of chemically
synthesized 1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂ was
measured using a vitamin D-dependent transcriptional
activation model system in which a vitamin D receptor
(VDR)-expressing plasmid pSG5-hVDR1/3 and a plasmid
p(CT4)⁴TKGH containing a Growth Hormone (GH)-gene, under
the control of a vitamin D-responsive element (VDRE)
were co-transfected into Green monkey kidney, COS-1
cells. DNA's for these two vectors were supplied by
Dr. Mark Haussler, Department of Biochemistry,
University of Arizona, Tucson, Arizona.
Tranfected cells were incubated with vitamin D metabolites and growth hormone production was measured. As shown in Table 2, 1α,24(S)-(OH)_2D_2 has significantly more activity in this system than 1α,24(R)-(OH)_2D_2.

**Table 2:** Vitamin D Inducible Growth Hormone Production in Transfected COS-1 Cells.

<table>
<thead>
<tr>
<th>Inducer</th>
<th>Molar Concentration</th>
<th>Total GH Production* (ng/ml)</th>
<th>Net vitamin D-inducible GH-production (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol</td>
<td></td>
<td>44</td>
<td>0</td>
</tr>
<tr>
<td>25-OH-D_3</td>
<td>10^7</td>
<td>245</td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>10^6</td>
<td>1100</td>
<td>1056</td>
</tr>
<tr>
<td></td>
<td>10^5</td>
<td>775</td>
<td>731</td>
</tr>
<tr>
<td>1α,25-(OH)_2D_3</td>
<td>10^-10</td>
<td>74</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>10^-9</td>
<td>925</td>
<td>881</td>
</tr>
<tr>
<td></td>
<td>10^-8</td>
<td>1475</td>
<td>1441</td>
</tr>
<tr>
<td>1α,24(S)-(OH)_2D_2</td>
<td>5x10^-10</td>
<td>425</td>
<td>381</td>
</tr>
<tr>
<td></td>
<td>5x10^-9</td>
<td>1350</td>
<td>1306</td>
</tr>
<tr>
<td></td>
<td>5x10^-8</td>
<td>1182</td>
<td>1138</td>
</tr>
<tr>
<td>1α,24(R)-(OH)_2D_2</td>
<td>10^-9</td>
<td>80</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>10^-8</td>
<td>1100</td>
<td>1056</td>
</tr>
<tr>
<td></td>
<td>10^-7</td>
<td>1300</td>
<td>1256</td>
</tr>
</tbody>
</table>

* Averages of duplicate determinations

**Example 5:** Affinity of 1α,24(S)-(OH)_2D_2 for the vitamin D receptor.

The affinity of 1α,24(S)-(OH)_2D_2 for the mammalian vitamin D receptor (VDR) was assessed using a commercially available kit of bovine thymus VDR and standard 1,25-(OH)_2D_2 solutions from Incstar (Stillwater, Minnesota). Purified 1α,24(S)-(OH)_2D_2 was quantitated by photodiode array spectrophotometry and assayed in the radioreceptor assay. The half-maximal binding of 1α,24(S)-(OH)_2D_2 was approximately 150 pg/ml whereas that of 1α,25-(OH)_2D_2 was 80 pg/ml. Thus, the 1α,24(S)-(OH)_2D_2 had a two-fold lower affinity for bovine thymus VDR than does 1α,25-(OH)_2D_2, indicating that 1α,24(S)-(OH)_2D_2 had potent biological activity.
Example 6: Relative affinities of 1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂ for the vitamin D receptor.

The relative affinities of 1α,24(R)-(OH)₂D₂ and 1α,24(S)-(OH)₂D₂ for the vitamin D receptor (VDR) were assessed using commercially available reagents of bovine thymus VDR and standard 1α,25-(OH)₂D₃ solutions from Incstar (Stillwater, Minnesota). The purified 1α,24(R)-(OH)₂D₂ and 1α,24(S)-(OH)₂D₂ epimers were quantitated by ultraviolet spectroscopy. The concentration of 1α,24(R)-(OH)₂D₂ required to produce the same displacement of ³H-1α,25-(OH)₂D₃ tracer from the receptor was 20 to 30 times that required for 1α,24(S)-(OH)₂D₂, as shown in Figure 4. These data indicate that the activity of the 1α,24(S)-(OH)₂D₂ epimer is significantly greater than that of the 1α,24(R)-(OH)₂D₂ epimer.

Example 7: Affinity of 1α,24(S)-(OH)₂D₂ for the vitamin D serum binding protein.

The affinity of 1α,24(S)-(OH)₂D₂ for the vitamin D serum binding protein (DBP) was assessed using vitamin D deficient rat serum according to known methods in the art. The data indicated that the 1α,24(S)-(OH)₂D₂ binding of DBP was at least 1000 times weaker than that for 25-OH-D₃. Given the strong binding of 1α,24(S)-(OH)₂D₂ for the VDR and weak binding for the DBP, this compound would tend to be taken up by target cells, thus possessing a potent biological activity. In addition, the weak binding by the DBP was indicative of more rapid clearance, allowing for low toxicity.

Thus, the preceding assays demonstrated that the new 1α,24(S)-(OH)₂D₂ exhibited a distinct and unique spectrum of activities—namely, high biological potency and low toxicity which clearly distinguished the compound from those of the prior art and from its 24(R) epimer.
Example 8: Generation of $1\alpha, 24(S)-(OH)_2D_2$ from vitamin D$_2$ and 24-OH-D$_2$.

Vitamin D$_2$ or 24-OH-D$_2$ was administered (either oral or intraperitoneal supplementation) to vitamin D-deficient rats. Lipid extracts of the plasma were prepared and the metabolites purified by the method of Horst et al. (Horst, R. L., Koszewski, N. J. and Reinhardt, T. A., Biochem., 29:578-82 (1990)) described below for synthesizing standard biological $1\alpha, 24-(OH)_2D_2$.

Standard biological $1\alpha, 24-(OH)_2D_2$ was synthesized in vitro from 24-OH-D$_2$ by incubating 10 µg of 24-OH-D$_2$ in flask containing 5 ml of 20% kidney homogenates made from vitamin D-deficient chicks. The product of this reaction was isolated by HPLC and identified by mass spectrometry. In the lipid extracts of the plasma from the vitamin D-deficient rats administered vitamin D$_2$ or 24-OH-D$_2$, one metabolite isolated co-migrated on HPLC with the standard $1\alpha, 24-(OH)_2D_2$, indicating that $1\alpha, 24-(OH)_2D_2$ is a natural metabolite of vitamin D$_2$. In contrast, comparable rats administered vitamin D$_3$ had no detectable 24-OH-D$_3$.

Example 9: Preferential production of $1\alpha, 24(S)-(OH)_2D_2$ with increased substrate concentrations in vitro.

Hep 3B cells were incubated with $1\alpha$-OH-D$_2$ as described above, at final concentrations of 1, 10, or 100 nM (Experiment 1), and 1 or 10 µM (Experiment 2) and $1\alpha, 24(S)-(OH)_2D_2$ was extracted and purified. The $1\alpha, 24(S)-(OH)_2D_2$ and $1\alpha, 25-(OH)_2D_2$ metabolites were quantitated by recovered radiolabel (Experiment 1) or by photodiode array spectrophotometry (Experiment 2). As shown in Table 3, the amount of $1\alpha, 24(S)-(OH)_2D_2$ increased relative to the amount of $1\alpha, 25-(OH)_2D_2$ as the substrate concentration was raised. This indicates that in this system $1\alpha, 24(S)-(OH)_2D_2$ was the predominant natural active metabolite of $1\alpha$-OH-D$_2$ at higher substrate concentrations.
TABLE 3

<table>
<thead>
<tr>
<th>EXPERIMENT</th>
<th>SUBSTRATE CONCENTRATION</th>
<th>PRODUCT FORMED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>mM</td>
<td>Ratio of 1α,24(S)-(OH)₂D₂ to 1α,25-(OH)₂D₂</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1:4</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>1:1</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>1.5:1</td>
</tr>
<tr>
<td>2</td>
<td>μM</td>
<td>Rate of Production, pmol per 10⁶ cells/day</td>
</tr>
<tr>
<td></td>
<td>1α,24(S)-(OH)₂D₂</td>
<td>1α,25-(OH)₂D₂</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>4.9</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>59</td>
</tr>
</tbody>
</table>

*N.D. means not detectable

Example 10: Production of 1α,24(S)-(OH)₂D₂ in osteoporotic women administered 1α-(OH)₂D₂.

An increase in the production of 1α,24(S)-(OH)₂D₂ relative to 1α,25-(OH)₂D₂ has also been observed by the present inventors in human females who received 1α-OH-D₂ as part of an investigation of that drug for the treatment of osteoporosis. Following either a single dose of 2 μg of 1α-OH-D₂ or daily doses of 8 μg/day for one week, blood was collected and analyzed for the metabolites 1α,24(S)-(OH)₂D₂ and 1α,25-(OH)₂D₂. Lipid was extracted from the blood, and the metabolites were purified by HPLC using standard methods and quantified with the radioreceptor assay produced by Incstar (Stillwater, Minnesota). One day after a single 2 μg dose, the level of 1α,24(S)-(OH)₂D₂ was undetectable with the 1α,25-(OH)₂D₂ level being approximately 11 pg/ml. In contrast, one day following the last dose of 8 μg, the level of 1α,24(S)-(OH)₂D₂ averaged 9 pg/ml with the 1α,25-(OH)₂D₂ level averaging 30 pg/ml.
Example 11: Dose ranging study in postmenopausal osteoporotic women.

Twenty postmenopausal osteoporotic women are enrolled in an open label study. The selected patients have ages between 55 and 75 years, and exhibit L2-L3 vertebral bone mineral density between 0.7 and 1.05 g/cm², as determined by measurements with a LUNAR Bone Densitometer (Lunar Corporation, Madison, Wisconsin).

On admission to the study, all patients receive instruction on selecting a daily diet containing 400 to 600 mg of calcium. Compliance to this diet is verified at weekly intervals by 24-hour food records and by interviews with each patient.

All patients complete a one-week baseline period, a five-week treatment period, and a one-week post-treatment observation period. During the treatment period, patients orally self-administer 1α,24(S)-dihydroxy vitamin D₃ at an initial dose of 0.5 μg/day for the first week, and at successively higher doses of 1.0, 2.0, 4.0, and 8.0 μg/day in each of the following four weeks. All doses are administered before breakfast.

Blood and urine chemistries are monitored on a weekly basis throughout the study. Key blood chemistries include fasting serum levels of calcium, phosphorus, osteocalcin, creatinine, and blood urea nitrogen. Key urine chemistries include 24-hour excretion of calcium, phosphorus, and creatinine.

Blood and urine data from this clinical study indicate that this compound does not adversely affect kidney function, as determined by creatinine clearance and blood levels of urea nitrogen; nor does it increase urinary excretion of hydroxyproline, indicating the absence of any stimulatory effect on bone resorption. The compound has no effect on any routinely monitored serum parameters, indicating the absence of adverse metabolic effects.
A positive effect of 1α,24(S)-dihydroxy vitamin D₃ on calcium homeostasis is evident from modest increases in 24-hour urinary calcium levels, confirming that the compound increases intestinal calcium absorption, and from increases in serum osteocalcin levels, indicating that the compound stimulates the osteoblasts.


A clinical study is conducted with postmenopausal osteoporotic out-patients having ages between 55 and 75 years. The study involves up to 120 patients randomly divided into three treatment groups and continues for 24 to 36 months. Two of the treatment groups receive constant dosages of 1α,24(S)-dihydroxy vitamin D₃ (u.i.d.; two different dose levels at or above 1.0 µg/day) and the other group receives a matching placebo. All patients maintain a normal intake of dietary calcium (500 to 800 mg/day) and refrain from using calcium supplements. Efficacy is evaluated by pre-and post-treatment comparisons of the patient groups with regard to (a) total body calcium retention, and (b) radial and spinal bone mineral density as determined by dual-photon absorptiometry (DPA) or dual-energy x-ray absorptiometry (DEXA). Safety is evaluated by comparisons of urinary hydroxyproline excretion, serum and urine calcium levels, creatinine clearance, blood urea nitrogen, and other routine determinations.

The results show that patients treated with 1α,24(S)-dihydroxy vitamin D₃ exhibit significantly higher total body calcium, and radial and spinal bone densities relative to patients treated with placebo. The monitored safety parameters confirm an insignificant incidence of hypercalcemia or hypercalciuria, or any other metabolic disturbance with 1α,24(S)-dihydroxy vitamin D₃ therapy.
Example 13: Prophylaxis of postmenopausal bone loss.

A clinical study is conducted with healthy postmenopausal women having ages between 55 and 60 years. The study involves up to 80 patients randomly divided into two treatment groups, and continues for 24 to 36 months. One treatment group receives a constant dosage of 1α,24(S)-dihydroxy vitamin D₃ (u.i.d.; a dose level at or above 1.0 μg/day) and the other receives a matching placebo. The study is conducted as indicated in Example 2 above.

The results show that patients treated with 1α,24(S)-dihydroxy vitamin D₃ exhibit reduced losses in total body calcium, radial or spinal bone densities relative to baseline values. In contrast, patients treated with placebo show significant losses in these parameters relative to baseline values. The monitored safety parameters confirm the safety of long-term 1α,24(S)-dihydroxy vitamin D₃ administration at this dose level.

Example 14: Management of hypocalcemia and the resultant metabolic bone disease in chronic hemodialysis patients.

A twelve-month, double-blind, placebo-controlled clinical trial is conducted with thirty men and women with renal disease who are undergoing chronic hemodialysis. All patients enter an 8-week control period during which time they receive a maintenance dose of Vitamin D₃ (400 IU/day). After this control period, the patients are randomized into two treatment groups: one group receives a constant dosage of 1α,24(S)-dihydroxy vitamin D₃ (u.i.d.; a dosage greater than 3.0 μg/day) and the other group receives a matching placebo. Both treatment groups receive a maintenance dosage of Vitamin D₃, maintain a normal intake of dietary calcium, and refrain from using calcium supplements. Efficacy is evaluated by pre- and post-treatment comparisons of the two patient groups with regard to (a)
direct measurements of intestinal calcium absorption, (b) total body calcium retention, (c) radial and spinal bone mineral density, or (d) determinations of serum calcium. Safety is evaluated by regular monitoring of serum calcium.

Analysis of the clinical data show that 1α,24(S)-dihydroxy vitamin D₃ significantly increases intestinal calcium absorption, as determined by direct measurements using a double-isotope technique. Patients treated with this compound show normalized serum calcium levels, stable values for total body calcium, and stable radial and spinal bone densities relative to baseline values. In contrast, patients treated with placebo show frequent hypocalcemia, significant reductions in total body calcium and radial and spinal bone density. An insignificant incidence of hypercalcemia is observed in the treated group.

Example 15: Medicament preparations.

A topical cream is prepared by dissolving 1.0 mg of 1α,24(S)-dihydroxy vitamin D₃ in 1 g of almond oil. To this solution is added 40 gm of mineral oil and 20 gm of self-emulsifying beeswax. The mixture is heated to liquefy. After the addition of 40 ml hot water, the mixture is mixed well. The resulting cream contains approximately 10 µg of 1α,24(S)-dihydroxy vitamin D₃ per gram of cream.

Example 16:

An ointment is prepared by dissolving 1.0 mg of 1α,24(S)-dihydroxy vitamin D₃ in 30 g of almond oil. To this solution is added 70 gm of white soft paraffin which had been warmed just enough to be liquefied. The ointment is mixed well and allowed to cool. This ointment contains approximately 10 µg 1α,24(S)-dihydroxy vitamin D₃ per gram of ointment.
Example 17:

To the ointment of Example 14 is added with thorough mixing 0.5 g of adenosine and 2.0 g of papaverine base, both dissolved in a minimum quantity of dimethyl sulfoxide. The additional ingredients are present to the extent of about 0.5 wt % (adenosine) and 2 wt % (papaverine base).

Example 18:

To the ointment of Example 14 is added with thorough mixing 10,000 U of Vitamin A dissolved in a minimum quantity of vegetable oil. The resultant ointment contains about 100 U Vitamin A per gram of the ointment.

Example 19:

A dermatological lotion is prepared by dissolving 1.0 mg of 1α,24(S)-dihydroxy vitamin D₃ in 100 g of dry propylene glycol. The lotion is stored in a refrigerator in a brown bottle and contains about 10 µg of 1α,24(S)-dihydroxy vitamin D₃ per gram of lotion.

Example 20:

In 1 g of almond oil is dissolved 0.2 mg of 1α,24-dihydroxy vitamin D₃. To the solution is added 40 g of mineral oil and 20 g of self-emulsifying beeswax, followed by 40 ml of hot water. The mixture is mixed well to produce a cosmetic cream containing about 2.0 µg of 1α,24(S)-dihydroxy vitamin D₃ per gram of cream.

Example 21:

To a cosmetic cream prepared according to example 18 is added 100 mg adenosine. The cream is mixed well and contains about 0.1 wt % adenosine.
Example 22:

An ointment is prepared by dissolving 100 μg of 1α,24(S)-dihydroxy vitamin D$_2$ in 30 g of almond oil. To the solution so produced is added 70 g white soft paraffin which had been warmed just enough to be liquified. The ointment is mixed well and allowed to cool. The ointment so produced contains about 1.0 μg of 1α,24-dihydroxy vitamin D$_2$ per gram of ointment.

Example 23:

To the cosmetic ointment of Example 18 is added with thorough mixing 200 U/g Vitamin A dissolved in a minimum amount of vegetable oil.

Example 24:

A cosmetic lotion is prepared by dissolving 300 μg of 1α,24-dihydroxy vitamin D$_2$ in 100 g of dry propylene glycol. The lotion is stored in a refrigerator in a brown bottle and contains about 3.0 μg 1α,24(S)-dihydroxy vitamin D$_2$ per gram of lotion.

Example 25: Dermatological testing.

Compositions containing 1α,24(S)-dihydroxy vitamin D$_2$ are evaluated for therapeutic efficacy of the composition in the topical treatment of dermatitis (contact and ectopic). The composition evaluated is an ointment containing 10 μg of 1α,24-dihydroxy vitamin D$_2$ per gram of ointment in a petrolatum-almond oil base. The control composition is identical except that it does not contain the active agent 1α,24(S)-dihydroxy vitamin D$_2$. The patients are treated in an out-patient clinic. They are instructed to use the preparation two times a day.

The ointment is as far as possible applied to a single lesion, or to an area of the disease. The ointment and its container are weighed before the
treatment starts and returned with any unused contents for reweighing at the end of the treatment.

The area of the lesion treated is estimated and recorded, and the lesion is photographed as required, together with suitable "control" lesions. The latter are preferably lesions of similar size and stage of development, either in the vicinity of the treated lesion or symmetrically contralateral. Relevant details of the photographic procedure are recorded so as to be reproduced when the lesions are next photographed (distance, aperture, angle, background, etc.). The ointment is applied twice daily and preferably left uncovered. The "control" lesions are left untreated, but if this is not possible, the treatment used on them is noted.

Evaluations of erythema, scaling, and thickness are conducted at weekly intervals by a physician, with the severity of the lesion rated from 0 to 3. The final evaluation is usually carried out at the end of four to six weeks of treatment. Those lesions treated with 1α,24(S)-dihydroxy vitamin D₃ have lower scores than the control lesions. An insignificant incidence of hypercalcemia is also observed.

Example 26: Epidermal cell differentiation and proliferation testing.

Human keratinocytes are cultured according to known modifications of the system originally described by Rheinwald and Green (Cell, vol. 6, p. 331 (1975)). The 1α,24(S)-dihydroxy vitamin D₃, dissolved in ethanol, is added to cells to yield a variety of concentrations between 0.05 and 5 μg/ml with the ethanol concentration not to exceed 0.5% v/v. Control cultures are supplemented with ethanol at a final concentration of 0.5% v/v.

Differentiation and proliferation of epidermal cells in culture is examined by:

1. quantitation of cornified envelopes;
2. quantitation of cell density of cells attached to disks;
3. monitoring transglutaminase activity; or
4. monitoring DNA synthesis by incorporation of $^3$H-thymidine.

Cultures incubated with 1α,24(S)-dihydroxy vitamin D$_2$ have more cornified envelopes, fewer attached cells, higher transglutaminase activity, and lower DNA synthesis than control cultures.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions, that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.

**Example 27:** Activity of 1α,24(S)-(OH)$_2$D$_2$ in HL-60 cell differentiation assay.

A dose-response study is conducted with 1α,24(S)-(OH)$_2$D$_2$ in the HL-60 cell differentiation assay as described by DeLuca and Ostrom (DeLuca, H. F. and Ostrem, V. K., *Prog. Clin. Biol. Res.*, vol. 259, pp. 41-55 (1988)). In this study, 1α,25-(OH)$_2$D$_3$ is used as a positive control and appropriate solvents are used as negative controls. The following variables are evaluated: nonspecific acid esterase activity, nitroblue tetrazolium (NBT) reduction, and thymidine incorporation. The results show that 1α,24(S)-(OH)$_2$D$_2$ has potent activity in promoting differentiation of HL-60 promyelocytes to monocytes.
Example 28: Antiproliferative activity of 1α,24(S)-(OH)₂D₃ in human cancer cell lines.

Dose-response studies are conducted with 1α,24(S)-(OH)₂D₃ in a battery of human cancer cell lines. These cell lines include, but are not limited to, the following: BCA-1 or ZR-75-1 (breast) and COL-1 (colon), as described by Shieh, H. L. et al. Chem. Biol. Interact., vol. 81, pp. 35-55 (1982). In this study, appropriate solvents are used as negative controls. The results show that 1α,24(S)-(OH)₂D₃ has potent (and reversible) antiproliferative activity, as judged by inhibition of thymidine incorporation.
CLAIMS

1. 1α,24(S)-Dihydroxy vitamin D₂.

2. A method for preventing or treating vitamin D deficiency-induced diseases comprising administering an effective amount of 1α,24(S)-dihydroxy vitamin D₂.

3. A method for the treatment of skin disorders comprising administering topically an effective amount of 1α,24(S)-dihydroxy vitamin D₂.

4. A prophylactic or therapeutic pharmaceutical composition for vitamin D deficient diseases, comprising a physiologically acceptable vehicle and an effective amount of 1α,24(S)-dihydroxy vitamin D₂.

5. A pharmaceutical composition comprising an amount effective to prevent or treat loss of bone mass or bone mineral content in a human being suffering from or predisposed to a depletive bone disorder of 1α,24(S)-dihydroxy vitamin D₂ in combination with a physiologically acceptable expedient.

6. A pharmaceutical composition comprising an amount effective to stabilize radial and spinal bone density in a human being suffering from renal osteodystrophy of 1α,24(S)-dihydroxy vitamin D₂ in combination with a physiologically acceptable expedient.

7. A method for preventing or treating loss of bone mass or bone mineral content in a human being experiencing or predisposed to loss of bone mass or bone mineral content, comprising administering to said human being an amount of 1α,24(S)-dihydroxy vitamin D₂ sufficient to prevent loss of bone mass or bone mineral content without causing hypercalcemia or hypercalciuria.
8. A method for stabilizing or increasing bone mass in a human being suffering from renal osteodystrophy, comprising administering to said human being an amount of 1α,24(S)-dihydroxy vitamin D₃ sufficient to stabilize or increase bone mass without causing hypercalcemia or hypercalciuria.

9. A composition for use in topical treatment of skin disorders, comprising a carrier suitable for topical application and 1α,24(S)-dihydroxy vitamin D₃.

10. The composition of claim 9, wherein the amount of 1α,24(S)-dihydroxy vitamin D₃ is between 0.01 µg and 50 µg per gram of composition.

11. The composition of claim 9, further comprising an agent from the group consisting of epithelialization-inducing agents, chromonols, β-agonists, anti-inflammatory agents and keratoplastic agents.

12. A method of preparing 1α,24(S)-dihydroxy vitamin D₃, comprising:
   (a) acetylatlng ergosterol to form its 3β-acetate;
   (b) reacting with a triazoline dione and ozonating to form the 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-cholene-3β-y1 acetate;
   (c) adding 3-methylbutan-2-one to 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-cholene-3β-y1 acetate to form (22E)5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl) cholesta-6,22-diene-24-one-3β-y1 acetate;
   (d) adding methylmagnesium bromide to (22E)5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl) cholesta-6,22-diene-24-one-3β-y1 acetate to form (22E)-5α,8α-(4-phenyl-3,5-dioxo-
1,2,4-triazolidine-1,2-diyl)-6,22-
ergostadiene-3β,24-diol;
(e) reducing the (22E)-5α,8α-(4-phenyl-3,5-dioxo-
1,2,4-triazolidine-1,2-diyl)-6,22-
ergostadiene-3β,24-diol to form 24-hydroxy
ergosterol;
(g) irradiating 24-hydroxyergosterol to form 24-
hydroxy vitamin D₂;
(h) tosylating 24-hydroxy vitamin D₂ in the
presence of dry pyridine to form 24-hydroxy
vitamin D₂ 3β-tosylate;
(i) solvolyzing 24-hydroxy vitamin D₂ tosylate to
form 24-hydroxy-3,5 cyclovitamin D₂;
(j) allylically oxidizing the 24-hydroxy-
3,5 cyclovitamin D₂ with selenium dioxide to
form 1α,24-dihydroxy cyclovitamin D₂; and
(k) hydrolyzing the 1α,24-dihydroxy
3,5 cyclovitamin D₂ with a mixture of
dimethylsulfoxide and an organic acid to form
an admixture of the 5,6 cis 1α,24-dihydroxy
and 5,6 trans 1α,24-dihydroxy vitamin D₂ and
forming a Diels-Alder adduct of the 5,6 trans
1α-hydroxy vitamin D₂ to allow purification to
yield 1α,24(S)-dihydroxy vitamin D₂.

13. The method of claim 12, wherein said
purification of step (k) comprises chromatographically
separating 1α,24-dihydroxy vitamin D₂ to yield
1α,24(S)-dihydroxy vitamin D₂.

14. A method of preparing 1α,24(S)-dihydroxy
vitamin D₂, comprising:
(a) tosylating 24-hydroxy vitamin D₂ to form
24-hydroxy vitamin D₂ tosylate;
(b) methanolyzing the 24-hydroxy vitamin D₂
tosylate to form 24-hydroxy
3,5 cyclovitamin D₂;
(c) oxidizing the 24-hydroxy 3,5 cyclovitamin D₂ to form 1α,24-dihydroxy-3,5-cyclovitamin D₂; and

(d) sequentially hydrolyzing subjecting to a Diels-Alder reaction, and purifying the 1α,24-dihydroxy-3,5 cyclovitamin D₂ to form 1α,24(S)-dihydroxy vitamin D₂.

15. A method of producing 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-cholene-3β-yl acetate, comprising reacting 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-cholene-3β-yl acetate with 3-methylbutan-2-one in the presence of butyllithium and dry tetrahydrofuran.

16. A method of producing (22E)-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-6,22-ergostadiene-3β,24-diol, comprising reacting 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-cholene-3β-yl acetate with a Grignard reagent.

17. A method of producing 24-hydroxy ergosterol, comprising reacting (22E)-5α,8α-(4-phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-6,22-ergostadiene-3β,24-diol with lithium aluminum hydride in the presence of dry tetrahydrofuran.

18. A method of producing 24-hydroxy vitamin D₂ tosylate, comprising reaction 24-hydroxy vitamin D₂ with toluenesulfonyl chloride in the presence of dry pyridine.


20. A method of producing 6-methoxy-1α,24-dihydroxy-3,5-cyclovitamin D₂, comprising allylically
oxidizing 6-methoxy-24-hydroxy-3,5-cyclovitamin D₂ with selenium dioxide.

21. A method for treating vitamin D deficiency-induced bone depletive diseases, comprising:
   (a) reducing ergosterol, under such conditions and in sufficient quantity to produce 24-
   hydroxyergosterol;
   (b) irradiating the 24-hydroxyergosterol to produce 24-hydroxy vitamin D₂;
   (c) hydroxylating the vitamin D₂ under such conditions and in sufficient quantity to
   produce 1α,24(S)-dihydroxy vitamin D₂;
   (d) purifying the 1α,24(S)-dihydroxy vitamin D₂; and
   (e) administering to a mammal suffering from a bone depletive disease an amount effective to
   prevent or reverse loss of bone mass or bone mineral content of 1α,24(S)-dihydroxy
   vitamin D₂ in admixture with a pharmaceutically acceptable vehicle.

22. (22E)5α,8α-(4-phenyl-3,5-dioxo-1,2,4-
   triazolidine-1,2-diyl) cholesta-6,22-diene-24-one-3β-yl acetate.

23. (22E)-5α,8α-(4-Phenyl-3,5-dioxo-1,2,4-
   triazolidine-1,2-diyl)-6,22-ergostadiene-3β,24-diol.

24. (22E)-5,7,22-Ergostatriene-3β,24-diol.

25. 24-Hydroxy ergosterol.

26. 24-Hydroxy vitamin D₂ tosylate.

27. 6-Methoxy-24-hydroxy-3,5-cyclovitamin D₂.
28. A method of preparing 24-hydroxy vitamin D₂, comprising:
   (a) acetyllating ergosterol to form its 3β-acetate;
   (b) reacting with a triazoline dione and ozonating
to form the 22-oxo-5α,8α-(4-phenyl-3,5-dioxo-
1,2,4-triazolidine-1,2-diyl)23,24-dinor-6-
cholene-3β-yl acetate;
   (c) adding 3-methylbutan-2-one to 22-oxo-5α,8α-(4-
phenyl-3,5-dioxo-1,2,4-triazolidine-1,2-
diyl)23,24-dinor-6-cholene-3β-yl acetate to
form (22E)5α,8α-(4-phenyl-3,5-dioxo-
1,2,4-triazolidine-1,2-diyl) cholesta-
6,22-diene-24-one-3β-yl acetate;
   (d) adding methyl magnesium bromide to (22E)5α,8α-
(4-phenyl-3,5-dioxo-1,2,4-triazolidine-
1,2-diyl) cholesta-6,22-diene-24-one-3β-yl
acetate to form (22E)-5α,8α-(4-phenyl-
3,5-dioxo-1,2,4-triazolidine-1,2-diyl)-
6,22-ergostadiene-3β,24-diol;
   (e) reducing the (22E)-5α,8α-(4-phenyl-3,5-dioxo-
1,2,4-triazolidine-1,2-diyl)-6,22-
ergostadiene-3β,24-diol to form 24-hydroxy
ergosterol; and
   (g) irradiating 24-hydroxyergosterol to form
24-hydroxy vitamin D₂.

29. A feed for mammals comprising
1α,24(S)-dihydroxy vitamin D₂ wherein normal consumption
of the feed by the mammals provides about 0.01 to about
1.0 μg/kg/day of 1α,24(S)-dihydroxy vitamin D₂.

30. A method for treating breast cancer,
comprising administering an effective amount of
1α,24(S)-dihydroxy vitamin D₂.

31. A method for treating colon cancer, comprising
administering an effective amount of 1α,24(S)-dihydroxy
vitamin D₂.
FIGURE 3
### A. CLASSIFICATION OF SUBJECT MATTER

**IPC(S):** C07C 401/00; C07J 9/00, 43/00, 75/00; A61K 31/59  
**US CL:** 514/167; 552/653, 546; 540/96

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
**U.S.** : 514/167; 552/653, 546; 540/96

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Chemical Abstracts - Structure Search

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>BIOCHEMISTRY, Vol. 29, No.2, issued 1990, R.L. Horst et al, &quot;1 α Hydroxylation of 24-Hydroxvitamin D2 Represents a Minor Physiological Pathway for the Activation of vitamin D2 in Mammals&quot;, pages 578-582.</td>
<td>1</td>
</tr>
<tr>
<td>Y</td>
<td>ANALYTICAL BIOCHEMISTRY, Vol.-162, issued 1987, N.J. Koszewski et al., &quot;Use of Fourier Transform 'H NMR in the Identification of Vitamin D2 Metabolites&quot;, pages 446-452.</td>
<td>1</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

<table>
<thead>
<tr>
<th>Character</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;A&quot;</td>
<td>earlier document published on or after the international filing date</td>
</tr>
<tr>
<td>&quot;E&quot;</td>
<td>document referring to an oral disclosure, use, exhibition or other means</td>
</tr>
<tr>
<td>&quot;L&quot;</td>
<td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td>
</tr>
<tr>
<td>&quot;O&quot;</td>
<td>document published prior to the international filing date but later than the priority date claimed</td>
</tr>
<tr>
<td>&quot;T&quot;</td>
<td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td>
</tr>
<tr>
<td>&quot;X&quot;</td>
<td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td>
</tr>
<tr>
<td>&quot;Y&quot;</td>
<td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td>
</tr>
<tr>
<td>&quot;Z&quot;</td>
<td>document member of the same patent family</td>
</tr>
</tbody>
</table>

Date of the actual completion of the international search: 03 DECEMBER 1993  
Date of mailing of the international search report: 12 JAN 1994

Name and mailing address of the ISA/US.  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Authorized officer: KIMBERLY KESTLER  
Telephone No. (703) 308-1235

Facsimile No. NOT APPLICABLE  
Form PCT/ISA/210 (second sheet)(July 1992)*
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US, A, 5,098,899 (GILBERT, ET AL) 24 MARCH 1992, see col. 4-5.</td>
<td>1,3,9,10</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,195,027 (DELUCA, ET AL) 25 MARCH 1980, see entire document.</td>
<td>1, 27</td>
</tr>
<tr>
<td>Y</td>
<td>US, A, 4,719,205 (DELUCA, ET AL) 12 JANUARY 1988, see col. 3-7.</td>
<td>12,14-21,28</td>
</tr>
</tbody>
</table>
## INTERNATIONAL SEARCH REPORT

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **☐** Claims Nos.:
   - because they relate to subject matter not required to be searched by this Authority, namely:

2. **☐** Claims Nos.:
   - because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. **☐** Claims Nos.:
   - because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

(Form PCT/ISA/208 Previously Mailed.)

Please See Extra Sheet.

1. **☒** As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. **☐** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. **☐** As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. **☐** No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- **☐** The additional search fees were accompanied by the applicant's protest.
- **☐** No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*
BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING
This ISA found multiple inventions as follows:

Group I. Claims 1-2, 4 & 12-21, drawn to 1(alpha), 24-Dihydroxy vitamin D₃ a process of making the same, and the method of using the compound for preventing or treating vitamin D deficient diseases, classified in Class 552, subclass 653.

Group II. Claims 3 and 9-11, drawn to a composition and method for treating skin disorders, classified in Class 514, subclass 167.

Group III. Claims 5 and 7, drawn to a composition and method for preventing or treating loss of bone mass (or) bone mineral content; classified in Class 514, subclass 167.

Group IV. Claims 6 and 8, drawn to a composition and method for stabilizing or increasing bone mass in humans suffering from renal osteodystrophy, classified 514, subclass 167.

Group V. Claim 22, drawn to the compound (22E)-5f, 8f-(4-phenyl-3, 5-dioxo-1, 2, 4-triazolidine-1,2-diyi) cholesta-6,22-diene-24-one-3B-y1 acetate, classified in Class 540, subclass 96.

Group VI. Claim 23, drawn to the compound (22E)-5f, 8f-(4-phenyl-3,5-dioxo-1, 2, 4-triazolidine-1,2-diyi)-6, 22-ergostadiene-3B, 24-diol, classified in Class 540, subclass 96.

Group VII. Claim 24, drawn to the compound (22E)-5, 7, 22-ergostatriene-3B, 24-diol, classified in Class 552 subclass 546.

Group VIII. Claim 25, drawn to the compound 24-hydroxy ergosterol, classified in Class 552, subclass 653.

Group IX. Claim 26, drawn to the compound 24-hydroxy vitamin D₃ tosylate, classified in Class 552, subclass 653.

Group X. Claim 27, drawn to the compound 6-Methoxy-24-hydrox-3,5-cyclovitamin D₃, classified in Class 552, subclass 653.

Group XI. Claim 28, drawn to a process of producing the compound 24-hydroxy vitamin D₃, classified in Class 552, subclass 653.

Group XII. Claim 29, drawn to a feed for mammal.

Group XIII. Claim 30, drawn to a method for treating breast cancer, classified in Class 514, subclass 167.

Group XIV. Claim 31, drawn to a method for treating colon cancer, classified in Class 514, subclass 167.